Press Release Details

Cerus Corporation CEO Stephen Isaacs talks to The Wall Street Transcript

January, 25 2000

NEW YORK, Jan. 25 /PRNewswire/ -- The Wall Street Transcript has published an in-depth interview with Stephen Isaacs, CEO of Cerus Corporation (Nasdaq: CERS), in which he talks at length about his company's future.

The entire 3,500-word interview is available free online at .

Isaacs states, "Cerus is developing products to make the blood supply safer for transfusion recipients. We have a platform technology, that stops reproduction of viruses, bacteria and cells. Based on this platform technology, we're also developing products for use in cancer therapy. Cerus was founded in 1991, and we have five major programs underway. Four of these programs are now in clinical trials, with two of them in Phase III."

Isaacs explains, "We also have another program that is designed to improve the outcome of bone marrow transplants. This program is currently in clinical trials for the treatment of advanced leukemia, and we hope to expand this program significantly during the next 12 to 18 months. So those are some of the specific accomplishments you can expect to see from Cerus over the next 12 to 24 months."

Looking forward, Isaacs states, "Our current decontamination products for platelets, plasma and red cells enter the marketplace, we see a number of other additional significant opportunities coming into play. As we go beyond blood component decontamination systems, we're looking at new products, including additional cancer therapies, treatments to prevent restenosis, and other important applications that we have not yet announced. So, we do see a very significant and expanding pipeline as the company goes forward."

This interview is included in The Wall Street Transcript's HEALTHCARE sector available at or by calling 212-952-7433.

The Wall Street Transcript is a premier weekly investment publication serving serious long-term investors for over 35 years. TWST offers free excerpts of analyst and money manager interviews featuring their recommendations at

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800-246-7673.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600